Slides on Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

Learn key considerations for the use of ART in older PWH. Topics include current data and recommendations on polypharmacy, drug-drug interactions, drug-disease state interactions, and cardiovascular risk considerations
Jonathan Appelbaum, MD, FACP, AAHIVS
Jens D. Lundgren, MD, DMSc
Format: Microsoft PowerPoint (.ppt)
File Size: 347 KB
Released: November 29, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

Expert insight on treatment strategies for NASH in patients living with HIV, from Clinical Care Options (CCO)

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 10, 2022 Expired: January 9, 2023

From Clinical Care Options (CCO) and Dr. Jürgen K. Rockstroh and Dr. Giada Sebastiani: Recommended approach for screening and diagnosing NASH in patients with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 10, 2022 Expired: January 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings